Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1Gynecologic 1

Conditions

Neoplasms 2Uterine Cervical Neoplasms 1Sarcoma, Ewing 1Neuroectodermal Tumors, Primitive 1Lymphoma 1Endometrial Neoplasms 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × PM 00104 × Clear all
NCT01222767 2021-10-29

Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy

PharmaMar

Phase 2 Completed
17 enrolled 20 charts
Sarcoma

Sarcoma, Ewing, Neuroectodermal Tumors, Primitive

NCT00900562 2021-10-28

Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy

PharmaMar

Phase 2 Terminated
19 enrolled 21 charts
Gynecologic

Uterine Cervical Neoplasms, Neoplasms, Endometrial Neoplasms

NCT00359294 2021-07-28

A Phase I Study of Zalypsis (PM00104) in Subjects With Advanced Malignant Solid Tumors or Lymphoma

PharmaMar

Phase 1 Terminated
12 enrolled 13 charts
Lymphoid

Lymphoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡